LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that will publish financial results for the third quarter of 2022, and provide an update on recent business developments on November 3, 2022.
The management team will host a conference call at 8:00am ET (1:00pm UK) on November 3rd. To access the call, register in advance here to get a local or toll-free phone number and your personal PIN.
A live webcast of the call will be available on the COMPASS Pathway website at: Financial results for the third quarter of 2022.
The webcast will also be available on the investors section from the COMPASS Pathways website. The webcast will be archived for 30 days.
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is to improve the lives of those suffering from mental health problems who are not helped by current treatments. We pioneered the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated an Innovative Therapy Designator by the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK, for treatment-resistant depression (TRD). We have completed a phase 2b clinical trial of psilocybin therapy for TRD, at 22 sites in Europe and North America, and are preparing to begin a phase 3 program by the end of 2022. This phase 2b trial was the most large randomized, controlled, double-blinded clinical trial of psilocybin therapy was conducted, and our primary data showed a statistically significant (p<0.001) and clinically relevant improvement in severity of depressive symptoms after three weeks for patients receiving received a single high dose of psilocybin COMP360 with psychological support. We are also conducting Phase 2 clinical trials of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US Our vision is a world of mental wellness. www.compasspathways.com.
Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public through our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media. (LinkedIn), including, but not limited to, investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls, and webcasts. The information we post on these channels and websites may be considered material information. As a result, we encourage investors, the media and others interested in us to periodically review the information posted on these channels, including the investor relations website. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The content of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any file under the Securities Act of 1933.
queries
Media: Amy Lawrence, [email protected], +44 7813 777 919
Investors: Stephen Schultz, [email protected], +1 401 290 7324
.
